279 related articles for article (PubMed ID: 28264200)
1. Monitoring Antiplatelet Therapy.
Orme R; Judge HM; Storey RF
Semin Thromb Hemost; 2017 Apr; 43(3):311-319. PubMed ID: 28264200
[TBL] [Abstract][Full Text] [Related]
2. High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values.
Leunissen TC; Peeters Weem SM; Urbanus RT; den Ruijter HM; Moll FL; Asselbergs FW; de Borst GJ
Eur J Vasc Endovasc Surg; 2016 Aug; 52(2):198-204. PubMed ID: 27236738
[TBL] [Abstract][Full Text] [Related]
3. Platelet function monitoring and clopidogrel.
Harper AR; Price MJ
Curr Cardiol Rep; 2013 Jan; 15(1):321. PubMed ID: 23250658
[TBL] [Abstract][Full Text] [Related]
4. How I use laboratory monitoring of antiplatelet therapy.
Michelson AD; Bhatt DL
Blood; 2017 Aug; 130(6):713-721. PubMed ID: 28600334
[TBL] [Abstract][Full Text] [Related]
5. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
Bernlochner I; Byrne RA; Kastrati A; Sibbing D
Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
[TBL] [Abstract][Full Text] [Related]
6. Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury.
Parry PV; Choi PA; Bauer JS; Panczykowski DM; Puccio AM; Okonkwo DO
Neurosurgery; 2017 Jan; 80(1):92-96. PubMed ID: 28362884
[TBL] [Abstract][Full Text] [Related]
7. Platelet function testing as a biomarker for efficacy of antiplatelet drugs.
Lordkipanidzé M; So D; Tanguay JF
Biomark Med; 2016 Aug; 10(8):903-18. PubMed ID: 27414976
[TBL] [Abstract][Full Text] [Related]
8. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
[TBL] [Abstract][Full Text] [Related]
9. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
[TBL] [Abstract][Full Text] [Related]
10. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
11. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
Smock KJ; Saunders PJ; Rodgers GM; Johari V
Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020
[TBL] [Abstract][Full Text] [Related]
12. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
[TBL] [Abstract][Full Text] [Related]
14. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
Tsantes A; Ikonomidis I; Papadakis I; Kottaridi C; Tsante A; Kalamara E; Kardoulaki A; Kopterides P; Kapsimali V; Karakitsos P; Lekakis J; Travlou A
Platelets; 2012; 23(6):481-9. PubMed ID: 22646492
[TBL] [Abstract][Full Text] [Related]
17. The role of laboratory monitoring in antiplatelet therapy.
Cattaneo M
Handb Exp Pharmacol; 2012; (210):471-94. PubMed ID: 22918743
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of platelet reactivity in patients with acute coronary syndromes.
Cavallari I; Nusca A; Ricottini E; Di Sciascio G
Cardiol Rev; 2014; 22(6):313-8. PubMed ID: 25050977
[TBL] [Abstract][Full Text] [Related]
20. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
